EGFR and cancer: However, in a recent study with the same S5 platform using the Oncomine Pan-Cancer Cell-Free Assay, the reproducibility of detection of the EGFR p.L858R mutation was relatively low with a VAF of 1% and the identification of the EGFR p.L858R mutation with a VAF of 0.5% was less sensitive, despite adequate coverage.